Evidence map›Paper›PMID 40549070›Full record

ArticleBreast cancer (Tokyo, Japan)2025

Correction: Real‑world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first‑ or second‑line treatment for hormone receptor-positive, HER2‑negative advanced or metastatic breast cancer.

Tetsuhiro Yoshinami, Yuko Takano, Yukinori Ozaki, Yukiko Kajiwara, Mitsugu Yamamoto, Ken-Ichi Watanabe, Masami Tsukabe, Fumie Fujisawa, Shigenori E Nagai, Nobuhiro Shibata and 13 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

Tetsuhiro YoshinamiDepartment of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, 2-2-E10 Yamadaoka, Suita, Osaka, 565-0871, Japan. yosinami-te@onsurg.med.osaka-u.ac.jp.ORCID http://orcid.org/0009-0000-8747-3641
Yuko TakanoDepartment of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan.ORCID http://orcid.org/0000-0002-3753-7683
Yukinori OzakiDepartment of Breast Medical Oncology, The Cancer Institute Hospital of JFCR, Tokyo, Japan.
Yukiko KajiwaraDepartment of Breast Surgery, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
Mitsugu YamamotoDepartment of Breast Oncology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, Japan.
Ken-Ichi WatanabeDepartment of Breast Oncology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, Japan.
Masami TsukabeDepartment of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, 2-2-E10 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Fumie FujisawaDepartment of Medical Oncology, Shiga General Hospital, Moriyama, Shiga, Japan.
Shigenori E NagaiDivision of Breast Oncology, Saitama Cancer Center, Kitaadachi-gun, Saitama, Japan.
Nobuhiro ShibataDepartment of Clinical Oncology, Kansai Medical University Hospital, Hirakata, Osaka, Japan.ORCID http://orcid.org/0000-0001-8647-5098
Chiya OshiroDepartment of Breast Surgery, Kaizuka City Hospital, Kaizuka, Osaka, Japan.
Hiroko BandoDepartment of Breast and Endocrine Surgery, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Nobuyuki TsunodaDepartment of Breast Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Aichi, Japan.ORCID http://orcid.org/0000-0002-4993-0028
Kazuhiko YamagamiDepartment of Breast Surgery and Oncology, Shinko Hospital, Kobe, Hyogo, Japan.
Kei KoizumiDepartment of Surgery 1, Division of Breast Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Masahiro TakadaDepartment of Breast Surgery, Kansai Medical University, Hirakata, Osaka, Japan.ORCID http://orcid.org/0000-0002-5954-1296
Naoko ToriguchiDepartment of Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K, Kobe, Hyogo, Japan.
Nobuyuki SekineDepartment of Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K, Kobe, Hyogo, Japan.
Tsutomu KawaguchiDepartment of Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K, Kobe, Hyogo, Japan.
Shigehira SajiDepartment of Medical Oncology, Fukushima Medical University, Fukushima, Japan.ORCID http://orcid.org/0000-0002-6732-8030
Yasuaki SagaraDepartment of Breast and Thyroid Surgical Oncology, Social Medical Corporation Hakuaikai Sagara Hospital, Kagoshima, Japan.
Satoshi MoritaDepartment of Biomedical Statistics and Bioinformatics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0002-4344-3317
Norikazu MasudaDepartment of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0002-7302-0278

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40549070
PMCPMC12394238

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.